Kyverna Therapeutics (KYTX) Invested Capital (2023 - 2026)
Kyverna Therapeutics posted quarterly Invested Capital of $195.6 million for Q1 2026, down 12.69% year-on-year from $224.0 million in Q1 2025, and down 15.8% on a QoQ basis from $232.3 million in Q4 2025.
Kyverna Therapeutics (KYTX) has 4 years of Invested Capital data on file, last reported at $195.6 million in Q1 2026.
- For the quarter ending Q1 2026, Invested Capital fell 12.69% year-over-year to $195.6 million; the trailing twelve-month figure through Mar 2026 stood at $195.6 million (down 12.69% YoY), and the FY2025 full-year result was $232.3 million, down 12.87% from the prior year.
- Invested Capital for Q1 2026 stood at $195.6 million, down from $232.3 million in the prior quarter.
- Across five years, Invested Capital topped out at $361.0 million in Q1 2024 and bottomed at -$111.8 million in Q3 2023.
- The 4-year median for Invested Capital is $195.6 million (2026), against an average of $149.6 million.
- The widest annual swing landed in 2024, when Invested Capital soared 2128.97%; it then slumped 49.8% in 2025.
- A 4-year view of Invested Capital shows it stood at -$13.1 million in 2023, then jumped by 2128.97% to $266.6 million in 2024, then retreated by 12.87% to $232.3 million in 2025, then slipped by 15.8% to $195.6 million in 2026.
- The last three Invested Capital figures came in at $195.6 million (Q1 2026), $232.3 million (Q4 2025), and $151.9 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Invested Cap. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 595,226.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 110.96 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 14.38 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 19.36 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 31.42 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 1.08 Bn |
| 10 | Kyverna Therapeutics | 497.98 Mn | 265.03 Mn | - | 195.58 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 195.58 Mn |
| Dec 31, 2025 | 232.28 Mn |
| Sep 30, 2025 | 151.95 Mn |
| Jun 30, 2025 | 184.38 Mn |
| Mar 31, 2025 | 224.01 Mn |
| Dec 31, 2024 | 266.59 Mn |
| Sep 30, 2024 | 302.71 Mn |
| Jun 30, 2024 | 333.51 Mn |
| Mar 31, 2024 | 360.99 Mn |
| Dec 31, 2023 | -13.14 Mn |
| Sep 30, 2023 | -111.81 Mn |
| Jun 30, 2023 | -97.20 Mn |
| Mar 31, 2023 | -84.61 Mn |